The chemical composition of commonly used chemotherapy drugs can be altered so that they only become active when they come into contact with palladium, and cancer patients could one day experience fewer side effects from chemotherapy since this discovery opens the door for more targeted treatments.
Oncology nurses are taught to always administer platinums before taxanes for IV chemotherapy regimens; does this still hold true when the taxane is ordered IV, and the platinum is ordered IP?
Receiving a chemotherapy regimen following the completion of radiation therapy resulted in longer survival in adults with low-grade gliomas compared with those who received radiation therapy alone.
Patients taking crizotinib for ALK-positive non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
Why do children with Down syndrome who are being treated for acute lymphocytic leukemia sometimes require oral leucovorin after intrathecal methotrexate administration?
Long-term results of an EORTC trial show that 5- fluorouracil (FU)-based adjuvant chemotherapy after preoperative chemoradiotherapy for patients with cT3-resectable T4 M0 rectal cancer does not improve survival or disease-free survival.
Doxorubicin accumulates within the mitochondria of cardiomyocytes and this accumulation promotes mitochondrial production of reactive oxygen species (ROS) and the accumulation of iron.
Researchers have developed a technique for creating nanoparticles that carry two different cancer-killing drugs into the body and then delivers those drugs to separate parts of the cancer cell where they will be most effective.
High-dose cytarabine in induction treatment improves the outcomes of adult patients with acute myeloid leukemia (AML).
Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study.
For patients with previously untreated chronic lymphocytic leukemia and coexisting conditions, combining an anti-CD20 antibody with chemotherapy is associated with improved outcomes, according to a study.
After a response to initial chemotherapy, treatment with radiotherapy and surgical removal of the breast tumor and nearby lymph nodes do not provide any additional benefit to patients with metastatic breast cancer.
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer.
Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene. These results were presented at the 2013 San Antonio Breast Cancer Symposium.
In a study of women with triple-negative breast cancer, adding carboplatin or Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely. This was reported at the 2013 San Antonio Breast Cancer Symposium.
I-SPY 2 has yielded positive results with the first drug to complete testing during the trial. Adding carboplatin and veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results presented at the 2013 San Antonio Breast Cancer Symposium.
For women with metastatic breast cancer who had elevated amounts of CTCs in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression. These phase 3 clinical trial results were presented at the 2013 San Antonio Breast Cancer Symposium.
Combining the monoclonal antibody gemtuzumab with standard chemotherapy significantly reduced the risk of relapse and increased rates of disease-free survival in pediatric patients with AML. Posttreatment relapse rates are a major indicator of potential for long-term survival in children with the disease.
Head and neck cancer treatments have high morbidity rates. Newer options reduce morbidities and offer patients better quality of life after treatment.
More than 80 percent of oncologists report being unable to prescribe preferred drug at least once in past six months.
Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful IM injection for more than 40 years, research suggests.
Two studies show increase in pathologic complete response with pre-op chemotherapy combinations.
The intestinal flora stimulates an person's immune responses to combat cancer during chemotherapy, according to newly published research.
The chemotherapy drug cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants through an immune system cell that evades the toxic effects of cyclophosphamide.
The occurrence of venous thromboembolism (VTE) is greater than has been identified in clinical trials, according to a large-scale analysis that assessed the real-world risk.
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
Giving trastuzumab and anthracyclines concurrently is not necessary to achieve a high rate of complete pathologic remission in HER2-positive breast cancer. The results of a recent phase III clinical trial show that administering the treatments sequentially is equally effective.
Adult patients with Burkitt lymphoma had excellent long-term survival rates—upwards of 90%—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.
Selectively targeting only cancer cells could help to avoid healthy cells and side effects from treatments.
A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small cell lung cancer.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|